AKT1 and cancer: These findings can be supported by Kenyon whereby it was noted that when CBD is administered in combination with other cancer treatment therapies, it promotes disruption intracellular signalling pathways, such as P13K/AKT/mTOR and ERK, and so enhances combinative treatment cell death outcomes [33].